Pop a bottle of Prosecco and get ready to shake your money-maker because Lionsgate is partnering with STX to develop scripted TV series inspired by Jennifer Lopez’s Hustlers and the raunchy 2016 comedy Bad Moms. The plan to put both projects into development is part of a new distribution deal between STXfilms and Lionsgate, the companies announced on Wednesday.
The Hustlers and Bad Moms TV series projects are in the early stages of development, and there is no word if the original cast or crew members will return for the episodic versions of either property.
Released in 2016, Bad Moms stars Mila Kunis (Black Swan, The Spy Who Dumped Me), Kristen Bell (The Good Place, Veronica Mars), and Kathryn Hahn (WandaVision, Glass Onion: A Knives Out Mystery) as three overworked and under-appreciated moms pushed beyond their limits. After succumbing to exhaustion, they ditch their conventional responsibilities for a jolt of long-overdue freedom, fun, and comedic self-indulgence. A sequel, A Bad Moms Christmas, was released in 2017. Both movies were received well by audiences, with the target demographic (overworked and under-appreciated moms) delighting in the franchise’s bold comedic approach and sense of fun. Because both films were R-rated, the Bad Moms series can lean into its crude humor, getting to the heart of what makes motherhood so challenging, rewarding, and maddening.
Meanwhile, director Lorene Scafaria’s crime comedy, Hustlers, earned $157.5+M at the global box office. Led by Jennifer Lopez, with Constance Wu, Julia Stiles, Bardi B, Lizzo, Keke Palmer, and more, the film is inspired by a viral New York Magazine article. Hustlers follows a crew of savvy former strip club employees who band together to turn the tables on their Wall Street clients.
Bad Moms and Hustlers include story elements that could transfer well to the small screen. A mother’s job never ends, and there are plenty of stories to tell from the 24/7 onslaught of motherhood. If the show casts well, I could see a Bad Moms series becoming a major hit for the studio, especially after moms have lived the pandemic life for the past few years.
Would you watch a TV series inspired by Hustlers or Bad Moms? Who would you cast in either project? Let us know in the comments below.
Director Zack Snyder let it be known months ago that there will be two cuts of the movies in his upcoming two-part sci-fi epic – consisting of Rebel Moon: A Child of Fire, which will be released through the Netflix streaming service on December 22nd and Rebel Moon Part 2: The Scargiver, which will reach Netflix on April 19, 2024. One cut will be something “anyone can enjoy and watch”, while the other cut will be a more explicit version that will allow fans to take “a deeper, harder dive” into the material. Now, during a Q&A on the Netflix site Tudum, Snyder revealed that the director’s cut of Rebel Moon: A Child of Fire will be nearly an hour longer than the regular cut!
Snyder said, “The director’s cut is close to an hour of extra content, so I think it’s a legitimate extended universe version. You really get to see a lot. It’s just more painted-in all the way. The director’s [cut] is a settle-in deep dive, which I have notoriously done throughout my career. I don’t know how I got into this director’s cut thing, but what I will say about it is that, for me, the director’s cuts have always been something I had to fight for in the past and nobody wanted it. It was this bastard child that I was always trying to put together because they felt like there was a deeper version. And with Netflix, we shot scenes just for the director’s cut. So in that way, it’s really a revelation because it gives that second kick at the can for big fans, like a real discovery that they would not [otherwise] get. I’m really excited about it!“
Snyder has always been open about the fact that he’s hoping “a massive IP and a universe that can be built out” from the foundation of Rebel Moon. He crafted the story for Rebel Moon with 300 co-writer Kurt Johnstad, and the pair wrote the screenplay with Army of the Dead co-writer Shay Hatten. The events of the two films, which draw inspiration from Seven Samurai, are set in motion when a peaceful colony on the edge of the galaxy is threatened by the armies of a tyrannical regent named Balisarius. Desperate, the colonists dispatch a young woman with a mysterious past to seek out warriors from neighboring planets to help them make a stand.
The films star Sofia Boutella (The Mummy), Charlie Hunnam (Sons of Anarchy), Djimon Hounsou (A Quiet Place Part II), Ray Fisher (Justice League), Doona Bae (The Host), Jena Malone (Sucker Punch), Staz Nair (Supergirl), E. Duffy (whose previous credits are all short films), Charlotte Maggi (MaveriX), Sky Yang (Tomb Raider), Michiel Huisman (Game of Thrones), Alfonso Herrera (Ozark), Cary Elwes (Saw), Corey Stoll (Ant-Man), Ed Skrein (Deadpool), Anthony Hopkins (Hannibal), and Stuart Martin (Army of Thieves).
Snyder, his wife Deborah Snyder, and Wesley Coller are producing the Rebel Moon films through their company Stone Quarry. Eric Newman is producing via his banner, Grand Electric, while Grand Electric’s Sarah Bowen executive produces.
Are you looking forward to the Rebel Moon movies, and are you interested in watching the different cuts? What do you think of Snyder shooting scenes specifically with a longer director’s cut in mind? Let us know by leaving a comment below.
CMX-2043, a novel, proprietary cytoprotective drug candidate, demonstrated excellent safety and tolerability in a Phase 1 single ascending and multiple ascending dose (SAD-MAD) clinical trial. CMX-2043 has previously demonstrated safety and efficacy in extensive preclinical pharmacology, toxicology and TBI translational studies. CMX-2043 will be Phase 2-ready by the first quarter of 2024.
GRAFTON, Mass., August 25, 2023 (Newswire.com)
-
Ischemix, Inc., a privately-held company focused on developing cytoprotective therapeutics for serious medical conditions, today announced that it has completed an 80-subject Phase 1 clinical trial to evaluate safety, tolerability and pharmacokinetics of its drug candidate, CMX-2043, in healthy human subjects.
The Phase 1 study was a two-part, double-blinded, randomized, placebo-controlled trial in which single ascending doses (SAD) of CMX-2043 were administered by brief intravenous infusion to 40 healthy male and female subjects. After completion of the SAD portion of the trial, 40 additional healthy male and female subjects were randomized to receive multiple ascending doses (MAD) of CMX-2043 or placebo by daily intravenous infusion for five days."This Phase 1 trial demonstrates that CMX-2043 has the potential for an excellent safety profile when given intravenously over a wide range of doses. There were no serious adverse events and all treatment-emergent adverse events were mild and self-limiting. Importantly, the Principal Investigator determined that few adverse events were drug-related," said Jerry O. Stern, MD, Chief Medical Officer of Ischemix. CMX-2043 also was shown to have a well-characterized pharmacokinetic profile demonstrating dose proportionality over the dose ranges studied."
"Successful accomplishment of the Phase 1, along with the anticipated completion of other Phase 2-enabling non-clinical studies, will allow us to conduct a meeting with FDA early in the first quarter of 2024," said David DeWahl, President and CEO of the Company. "We are currently in the process of designing the protocol for a Phase 2 trial of CMX-2043 in TBI patients."
CMX-2043 has previously demonstrated safety and efficacy in rodent models at two laboratories and in porcine models at two additional laboratories. These successful preclinical efficacy results were achieved in endpoints measuring cognition, behavior, motor skills and MRI analysis.
Altasciences Company, Inc. a contract research organization offering a broad array of drug development services, performed the Phase 1 trial at its Montreal, Quebec, Canada facility.
The Phase 1 trial and certain related costs were funded in part by an award granted to Ischemix by US Army Medical Research and Development Command (USAMRDC), Combat Casualty Care Research Program (CCCRP), in collaboration with the Medical Technology Enterprise Consortium (MTEC), a 501(c)(3) biomedical technology consortium. (a)
About TBI
There are currently no TBI-specific pharmaceutical therapies approved for the treatment of patients suffering a brain injury. The Center for Disease Control reports that in the U.S. in 2014, there were approximately 2.9 million TBI-related emergency department visits. It is estimated that each year TBI is responsible for approx. 60,000 deaths and causes 80,000 individuals to have permanent disabilities. The annual direct and indirect costs of TBI in the U.S. are believed to be approx. $77 billion.
About CMX-2043
CMX-2043 is a pleiotropic (multi-modal), cytoprotective, small molecule drug. The compound exhibits a number of mechanistic properties that may act in concert to attenuate the secondary biochemical and cellular dysfunctions following acute TBI.
CMX-2043 is the subject of issued composition-of-matter and use patents in territories around the world.
About Ischemix, Inc.
Ischemix is a privately-held drug development company based in Grafton, MA. The primary focus of the Company is the development of its lead compound, CMX-2043, for treatment of TBI.
About U.S. Army Medical Research and Development Command
The U.S. Army Medical Research and Development Command is the Army's medical materiel developer, with responsibility for medical research, development, and acquisition. USAMRDC produces medical solutions for the battlefield with a focus on various areas of biomedical research, including military infectious diseases, combat casualty care, military operational medicine, and medical chemical and biological defense. https://mrdc.health.mil
About Neurotrauma at Combat Casualty Care Research Program
The Neurotrauma and Traumatic Brain Injury Portfolio is a requirements-based program that seeks to improve the far-forward capabilities of military diagnostic and treatment for the spectrum of TBI severities, with emphasis on moderate and severe TBI and polytrauma under Multi-Domain Operations in prolonged field care scenarios. https://cccrp.health.mil/Pages/default.aspx
About MTEC
MTEC is a biomedical technology consortium collaborating with multiple government agencies under a 10-year renewable Other Transactional Agreement with the U.S. Army Medical Research and Development Command. MTEC is managed by Advanced Technology International. To find out more about MTEC, visit mtec-sc.org.
For media questions, please contact:
David A. DeWahl, Jr. President and CEO 203-561-0806 or [email protected]
(a) This work was supported by the Assistant Secretary of Defense for Health Affairs endorsed by the Department of Defense, in the amount of $2,966,519, through the Medical Technology Enterprise Consortium under Award No. MT20015.039. Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the Assistant Secretary of Defense for Health Affairs or the Department of Defense.
Contact Information:
David DeWahl
President and CEO [email protected]
2035610806
RYE BROOK, N.Y., August 25, 2023 (Newswire.com)
-
Bona Fide Masks Corp., The Trusted Source™ for authentic, protective masks, stands ready to assist customers with their KN95 and N95 mask purchases to help keep them safe. With news of new COVID-19 variants emerging, Bona Fide Masks® is poised to help customers with tens of millions of masks in inventory ready to ship.
As part of a fourth-generation, family-owned and -operated group of businesses, Bona Fide Masks remains committed to best corporate practices, focusing on product authenticity and complete supply chain transparency. Explains company President Bill Taubner, "We are proud to offer high-quality, authentic masks that meet standards, especially as we head into Fall. We have the most transparent, strongest, and secure supply chain in the mask industry and are delighted to continue our relationships with acclaimed mask manufacturers, such as Powecom® and Harley®. Bona Fide Masks is honored to be the exclusive U.S. distributor for Powecom® KN95 and Harley® KN95. No order is too big or too small for us!"
Notably, Bona Fide Masks Corp. is the only mask distributor in the U.S. to earn ISO 9001 certification. The ISO vetting process includes all aspects of the company's business, including purchasing, supply chain integrity, logistics, delivery, infrastructure, testing, human resources, finance, and accounting. By securing IS0 9001 certification, Bona Fide Masks has underscored its unwavering commitment to its customers and its business partners, meeting and exceeding high-level international standards. The company remains committed to delivering premier products, using safe and sustainable processes. Operating under the ISO 9001:2015 standard helps ensure that Bona Fide Masks' customers receive authentic, high-quality products that meet or exceed strict standards.
The mask marketplace is complicated and confusing for many. In response, Bona Fide Masks has reinforced its commitment to providing authentic masks through transparency and supply chain integrity, featuring an authenticity statement from ownership, which is available here: https://bonafidemasks.com/insights/authenticity-statement/. The company never purchases from agents, middlemen, brokers, resellers, dealers, closeout companies, intermediaries, or third parties. Bona Fide Masks also performs in-house testing of masks using a recognized respirator tester, designed specifically for testing filter media. Following extensive research, Bona Fide Masks purchased an innovative and highly efficient 100X Automated Filter Tester from medical device leader Air Techniques International (ATI). This ATI machine is designed for quality control validation of filter media, replaceable particulate filters and masks used in medical and industry hygiene applications. The 100X meets leading industry standards such as NIOSH 42 CFR Part84, GB 2626, EN 1327-7:2019 and ASTM F3502-21. The 100X is designed for testing N95, KN95, FFP and P100 respirator masks.
More about Ball Chain Manufacturing Co., Inc., and Bona Fide Masks Corp.:
The current owners' great-grandfather and grandfather started Ball Chain Manufacturing Co., Inc. (Ball Chain) in a small garage behind their home in the Bronx, NY. The company has been family-owned and -operated since 1938. Ball Chain is now the world's largest manufacturer of ball chains (www.ballchain.com), seen on military dog tags, ceiling fans, handbags, and light pulls, among many other goods. The company manufactures more than 3 million feet of product per week at its Mount Vernon, New York, factory (all ball chains are made in the USA). Ball Chain is the exclusive supplier to the U.S. military for the iconic dog tag ID necklace worn by U.S. servicemen and women, and the company takes tremendous pride in everything it does.
Originally a division of Ball Chain, Bona Fide Masks Corp. handles warehousing and distribution with the utmost focus, systematically employing proven, regimented processes and protocols, as supply chain security and transparency are its highest priorities. In this regard, Bona Fide Masks is proud to issue statements of authenticity, providing further confidence to its customers and reinforcing its commitment to supply chain integrity.
Contact Information:
Bill Taubner
President [email protected]
914.664.7500
VENICE, Calif., August 25, 2023 (Newswire.com)
-
Leading in beauty and entrepreneurship, SUGARED + BRONZED, the luxury sugaring and sunless tanning brand, announces the grand opening of its 20th location. This accomplishment accentuates the brand's esteemed reputation in the beauty world.
Established in 2012, SUGARED + BRONZED has consistently highlighted its commitment to natural, high-quality products, exceptional services, and unparalleled customer experiences. Its passionate approach to beauty and the support of its elite clientele has spearheaded its rapid expansion across prime metropolitan areas.
Courtney Claghorn, President and co-founder, remarked, "From our humble beginnings in my apartment living room, our mission has always been to provide our clients with an exceptional experience. Our 20th location is rewarding and motivating. It's a testament to our incredible team's hard work and fantastic client loyalty."
Currently, the brand boasts of locations in New York City, Los Angeles, Austin, Dallas, Philadelphia, and Orange County — and coming soon to Miami, Houston, and Brooklyn.
The latest location in Venice, California, is infused with the brand's iconic chic aesthetic, ensuring that clients — celebrities and beauty aficionados alike — are enveloped in luxury from the moment they step in. As always, the focus remains on delivering top-tier sugaring and tanning services in a serene, upscale ambiance.
SUGARED + BRONZED will host a grand launch event on Sept. 14, 2023, to celebrate this landmark achievement. Attendees can look forward to a firsthand experience of the new location's services, enjoy complimentary bites and drinks, and meet the brand's expert team. Guests will also receive gift bags with exclusive SUGARED + BRONZED products, even its newest product S+B Sheer Sunscreen.
With 20 locations and an ever-expanding horizon, SUGARED + BRONZED's dedication to excellence remains undiminished. The brand fervently looks forward to reaching and delighting new communities, continually evolving its beauty philosophy, and setting unparalleled standards in the industry.
Founded in 2012, SUGARED + BRONZED stands out as a frontrunner in sugaring and sunless tanning. Committed to offering holistic beauty treatments, the brand is celebrated for using natural products, impeccable service, and a rejuvenating ambiance. Its unmatched approach to client satisfaction and endorsements from top-tier celebrities have propelled it to an elite spot in the beauty industry, evident by its widespread growth and unyielding client loyalty.
A trailer has been unveiled for The Marsh King’s Daughter, a psychological thriller starring Daisy Ridley and Ben Mendelsohn
Lionsgate and Roadside Attractions have unveiled a trailer for the psychological thriller The Marsh King’s Daughter, which is set to reach theatres on October 6th. To find out whether or not this is a movie you’ll want to head out to see on the big screen, check out the trailer in the embed above!
An adaptation of the Karen Dionne bestseller of the same name, The Marsh King’s Daughter was directed by Neil Burger (Limitless, Divergent) with Daisy Ridley (the Star Wars sequel trilogy) taking on the title role. Scripted by Mark L. Smith (The Revenant) and Elle Smith (earning her first screenwriting credit), the film adaptation follows a woman with a secret past who will venture into the wilderness she left behind to confront the most dangerous man she’s ever met: her father. Helena’s (Daisy Ridley) seemingly ordinary life hides a dark and dangerous truth: her estranged father is the infamous Marsh King (Ben Mendelsohn), the man who kept her and her mother captive in the wilderness for years. When her father escapes from prison, Helena will need to confront her past. Knowing that he will hunt for her and her family, Helena must find the strength to face her demons and outmaneuver the man who taught her everything she knows about surviving in the wild.
Ridley is joined in the cast by Ben Mendelsohn (Captain Marvel), Garrett Hedlund (TRON: Legacy), Caren Pistorius (Unhinged), Gil Birmingham (Yellowstone), and Brooklynn Prince (Cocaine Bear).
Black Bear Pictures financed the project. The Marsh King’s Daughter was produced by Black Bear’s Teddy Schwarzman, Anonymous Content’s Keith Redmon, and Mark L. Smith. Michael Heimler, Charles Miller, Cliff Roberts, Robert Simonds, Adam Fogelson, John Friedberg, and Samuel J. Brown served as executive producers.
The source novel (buy a copy HERE) was released in 2017 and has the following description:
Helena Pelletier has a loving husband, two beautiful daughters, and a business that fills her days. But she also has a secret: she is the product of an abduction. Her mother was kidnapped as a teenager by her father and kept in a remote cabin in the marshlands of Michigan’s Upper Peninsula. Helena, born two years after the abduction, loved her home in nature, and despite her father’s sometimes brutal behavior, she loved him, too… until she learned precisely how savage he could be.
More than twenty years later, she has buried her past so soundly that even her husband doesn’t know the truth. But now her father has killed two guards, escaped from prison, and disappeared into the marsh. The police begin a manhunt, but Helena knows they don’t stand a chance. Knows that only one person has the skills to find the survivalist the world calls the Marsh King — because only one person was ever trained by him: his daughter.
What did you think of the trailer for The Marsh King’s Daughter? Will you be watching this movie on the big screen in October? Let us know by leaving a comment below.
The movie seems interesting to me, so I will definitely be checking it out.
NEW YORK, August 25, 2023 (Newswire.com)
-
Software company TikaMobile has launched conversational and generative AI solutions, powered by ChatGPT that enhance the efficiency of field teams. The advanced AI solution covers three primary areas: publication analysis, medical insights and engagement analysis, and SOP and field info guidance.
TikaMobile's novel solution leverages an AI chat module implemented with the TikaMSL platform, offering users the flexibility of using it as a standalone solution or integrating it seamlessly with existing CRMs.
The publication analysis element of TikaMobile's solution enables field medical teams to better understand the scientific share of voice (SSOV) through systematic comparative analysis of scientific literature. Users can ask questions based on trends, point of view, sentiment, competitive outlook, etc.
TikaMobile's advanced conversational and generative AI reduces the time for field medical teams to research the work of their key opinion leaders (KOLs) and access critical industry trends for optimized decision-making.
Through medical insights and engagement analysis, TikaMobile enables teams to answer on-demand queries about gathered medical insights, the impact generated by these data, and the outlook of KOL engagements. These smart AI capabilities can help create ad-hoc reports for broader use cases beyond field medical teams.
"Medical Affairs is challenged with increasingly difficult-to-manage data and need for fulfilling complex objectives while showcasing the impact. TikaMobile aims to elevate the performance of planning and execution among field medical using generative AI. We see teams using this to gain visibility into unstructured data and converting insights into action," said Manish Sharma, CEO & Co-Founder, TikaMobile.
TikaMobile's SOP and field info guidance components equip medical field teams with AI-driven FAQ functionality. TikaMobile's generative AI learns from real-world customer SOPs and guidelines, keeping medical teams keenly informed about the best approach toward regulating complex activities.
TikaMobile launched these latest offerings in response to recent trends in medical affairs and omnichannel marketing, complementing healthcare personnel (HCP) engagement with AI and machine learning precision.
About TikaMobile
TikaMobile is a Strategic Planning and CRM+BI provider dedicated to creating innovative solutions for the life sciences industry. Tikamobile offers a comprehensive suite of products, including TikaMSL (solution specifically designed for Medical Affairs), TikaDevice (commercialization and sales enablement for Medical Devices), TikaPayer (dedicated for helping Market Access manage payers), TikaPharma (catered to pharmaceutical sales teams), and TiKaNAM (for national account managers). The company works towards empowering the life sciences with mobile and analytical advantages.
Visit TikaMobile.com for media enquiries or to learn more about their latest integrated solutions.
Contact Information:
Mia Shibly
Senior Business Development Manager [email protected]
917-302-0071
LIVONIA, Mich., August 25, 2023 (Newswire.com)
-
In calendar year 2022, Trinity Health Integrated Care (THIC) ACO, a Medicare Shared Savings Program (MSSP) Accountable Care Organization coordinated high-quality care for over 130,000 lives saving Medicare $56 million, with earned shared savings of $41.2 million to THIC ACO and its participating providers.
THIC ACO is one of very few renewing ACOs earning shared savings every year of participation. Since the ACO's launch in 2017, THIC has earned $126 million with an average quality score of 93% and engaged thousands of providers in transforming care for their Medicare beneficiaries. THIC continues to care for these Medicare beneficiaries across nine states in 2023.
Other Trinity Health ACOs in Michigan, Massachusetts, Connecticut, and Iowa also contributed to successful outcomes. Together with the THIC ACO, they coordinate high-quality efficient care for over 255,000 Medicare beneficiaries.
"We are committed to our mission of improving the health of the patients, families and communities we serve," said Emily Brower, senior vice president, Clinical Integration and Physician Services for Trinity Health. "Our ACOs enable us to do just that while spending smarter on the preventive care that keeps our patients healthier."
ACOs accept accountability for the quality, cost, and experience of care of the assigned beneficiary population. ACOs provide Medicare beneficiaries with high-quality, coordinated care including getting them the proper care when they need it, increasing preventive care, avoiding unnecessary service duplication, and preventing medical errors.
"With this achievement, our teams again show their commitment to continuous improvement. The challenges brought on by the pandemic gave us opportunities to be proactive in our outreach to high-risk patients through expanded capabilities including telehealth, home visits, post-acute care and remote monitoring," said Dan Roth, M.D., executive vice president, and chief clinical officer for Trinity Health.
In 2022, Trinity Health's MSSP ACOs ranged from upside-only to Enhanced two-sided financial risk arrangements representing the most significant risk in Medicare Shared Savings Program tracks. This means, from one year to the next, and depending on performance, Trinity Health Medicare Shared Savings ACOs either share in savings or are required to share in Medicare losses and repay a portion to Medicare.
Trinity Health is a strong proponent of value-based care delivery. We have 17 Clinically Integrated Networks (CINs) that are accountable for approximately two million lives across the country through alternative payment models. Our health care system participates in 14 markets with Medicare Shared Savings Program (MSSP) Accountable Care Organizations (ACOs), which includes 11 markets partnering in one national MSSP Enhanced Track ACO, Trinity Health Integrated Care. All of these markets participate in the "enhanced track," which qualifies as an advanced alternative payment model (AAPM). Two of the 14 markets also participate in CPC+. In addition, we participated in the Bundled Payments for Care Improvement Advanced (BPCIA) initiative and the Comprehensive Care for Joint Replacement (CJR) program across 37 hospitals.
About Trinity Health
Trinity Health is one of the largest not-for-profit, Catholic health care systems in the nation. It is a family of 123,000 colleagues and more than 26,600 physicians and clinicians caring for diverse communities across 26 states. Nationally recognized for care and experience, the Trinity Health system includes 88 hospitals, 135 senior care locations, the second-largest PACE program in the country, 136 urgent care locations and many other health and well-being services. Trinity Health has 15 medical groups with 1,324 primary care providers and 4,193 specialty care providers. Based in Livonia, Michigan, its annual operating revenue is $21.5 billion with $1.4 billion returned to its communities in the form of charity care and other community benefit programs. Trinity Health is committed to serving as a critical provider in our communities and coordinating care across settings and the care continuum, with 41% of our revenue coming from Medicare and 18% from Medicaid and uninsured patients.
Worthwhile Wear's 2023 Act Challenge Worthwhile Wear's 2023 Act Challenge was open to any and all participants. Over 850 people completed miles to raise awareness of the issue human trafficking by running, biking, walking, swimming and paddling
PHILADELPHIA, August 25, 2023 (Newswire.com)
-
On July 30, we recognized "World Day Against Trafficking" and on that same day Worthwhile Wear released the results of the national "Act Challenge." Participants and supporters from all over the globe logged miles in their communities and raised awareness about human trafficking with their actions by completing more than 192,000 miles. Worthwhile Wear operates a variety of restorative programs supporting survivors of trafficking and created the "Act Challenge'' as a way for the larger community to get involved. "When people hear about human trafficking, they want to act and get involved, so we created a way for people of all ages, abilities and locations to join with us in providing care to survivors, while also raising awareness about this growing issue," shared Dan Emr, Founder and Executive Director of Worthwhile Wear. As the challenge ran from May 1st to July 30th, individuals, groups, businesses, schools, churches and people from all over joined the mission by unlocking pledged dollars with every mile logged. Through the generosity of the Act Challenge sponsors and the efforts of all those who logged miles, over $102,000 was raised through the event which in turn will enable Worthwhile Wear to continue providing community outreach, long-term housing, employment, counseling, and restorative services to survivors of human trafficking. Since over 40 million people are trafficked worldwide, many survivors do not have access to resources for dealing with trauma, abuse, and addiction. Worthwhile Wear is forging a path for everyone to be a part of the solution. Dan Emr, Executive Director and Founder of Worthwhile Wear, is available for in-person or virtual interviews to discuss this event and the issue of human trafficking. Visit www.WorthwhileWear.org to learn more.
Worthwhile Wear is a 501(c)3 non-profit dedicated to reaching lives affected by human trafficking and restoring these survivors with a sense of belonging and worth. The road to healing requires a comprehensive response. It's not enough to offer a single solution, which is why Worthwhile Wear first engages survivors where they are, in our communities, then offers long-term stability with safe housing, and finally provides them with opportunities for financial independence by employment through its thrift stores. This wraparound approach is how Worthwhile Wear offers the most comprehensive services to survivors of trafficking in the state of Pennsylvania.
BOSTON, August 25, 2023 (Newswire.com)
-
Radical Imaging LLC, a pioneer in medical imaging informatics, interoperability, and integrations, announced today that it has joined NVIDIA Inception, a program that nurtures startups revolutionizing industries with technological advancements.
Radical Imaging's new product, FlexView, is a professionally supported, SaaS cloud-native medical imaging viewer based on the Open Health Imaging Foundation (OHIF) framework. It is a commercial-grade, production-ready solution that can easily be incorporated into any medical imaging system, seamlessly providing viewing and analysis capabilities for any type of medical image or workflow. FlexView adds to OHIF's extensibility model by introducing the ability to deploy plug-ins at runtime. This is crucial to enable the addition of new features dynamically, such as AI-based tools, without causing disruptions or system downtime.
Joining NVIDIA Inception will help Radical Imaging accelerate FlexView's integration with MONAI in order to unlock AI capabilities in FlexView. The program will also offer Radical Imaging the opportunity to collaborate with industry-leading experts and other AI-driven organizations.
"We're excited to join the list of startups in NVIDIA Inception, and we're grateful to work with NVIDIA. Considering how fast-moving AI is right now, this program gives us confidence that our viewing solution will be able to leverage the advances in AI, even as the field continues to evolve," said Rob Lewis, CEO of Radical Imaging.
NVIDIA Inception helps startups during critical stages of product development, prototyping, and deployment. Every NVIDIA Inception member gets a custom set of ongoing benefits, such as NVIDIA Deep Learning Institute credits, preferred pricing on NVIDIA hardware and software, and technological assistance, which provides startups with the fundamental tools to help them grow.
About Radical Imaging LLC
Radical Imaging is a software company focused entirely on medical imaging. It offers software system design and planning, contract software development, and consulting to help its partners solve their most challenging medical imaging problems using modern cloud and web platforms like Cornerstone.js and OHIF, which it co-developed with Massachusetts General Hospital. In 2023, Radical Imaging will be releasing its first commercial product, FlexView, a commercial version of OHIF. For more information, visit RadicalImaging.com.
